Journal of Vaccine Research 2024, Vol.14, No.4, 183-195 http://medscipublisher.com/index.php/jvr 194 Khong H., and Overwijk W.W., 2016, Adjuvants for peptide-based cancer vaccines, Journal for Immunotherapy of Cancer, 4: 1-11. https://doi.org/10.1186/s40425-016-0160-y PMid:27660710 PMCid:PMC5028954 Kuai R., Ochyl L., Bahjat K., Schwendeman A., and Moon J.J., 2017, Designer vaccine nanodiscs for personalized cancer immunotherapy, Nature Materials, 16(4): 489-496. https://doi.org/10.1038/nmat4822 PMid:28024156 PMCid:PMC5374005 Lee W., and Suresh M., 2022, Vaccine adjuvants to engage the cross-presentation pathway, Frontiers in Immunology, 13: 940047. https://doi.org/10.3389/fimmu.2022.940047 PMid:35979365 PMCid:PMC9376467 Li W.H., and Li Y.M., 2020, Chemical strategies to boost cancer vaccines, Chemical Reviews, 120(20): 11420-11478. https://doi.org/10.1021/acs.chemrev.9b00833 PMid:32914967 Li W.H., Su J.Y., and Li Y.M., 2022, Rational design of T-cell-and B-cell-based therapeutic cancer vaccines, Accounts of Chemical Research, 55(18): 2660-2671. https://doi.org/10.1021/acs.accounts.2c00360 PMid:36048514 Luchner M., Reinke S., and Milicic A., 2021, TLR agonists as vaccine adjuvants targeting cancer and infectious diseases, Pharmaceutics, 13(2): 142. https://doi.org/10.3390/pharmaceutics13020142 PMid:33499143 PMCid:PMC7911620 Melssen M., Petroni G., Chianese-Bullock K., Wages N., Grosh W., Varhegyi N., Smolkin M., Smith K., Galeassi N., Deacon D., Gaughan E., and Slingluff C.L., 2019, A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients, Journal for Immunotherapy of Cancer, 7: 1-13. https://doi.org/10.1186/s40425-019-0625-x PMid:31248461 PMCid:PMC6598303 Meneveau M.O., Kumar P., Lynch K.T., Patel S.P., and Slingluff C.L., 2022, The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling, Journal for Immunotherapy of Cancer, 10(3). https://doi.org/10.1136/jitc-2021-003533 PMid:35277457 PMCid:PMC8919469 Mesa C., and Fernández L.E., 2004, Challenges facing adjuvants for cancer immunotherapy, Immunology and Cell Biology, 82(6): 644-650. https://doi.org/10.1111/j.0818-9641.2004.01279.x PMid:15550123 Seya T., Shime H., Takeda Y., Tatematsu M., Takashima K., and Matsumoto M., 2015, Adjuvant for vaccine immunotherapy of cancer-focusing on Toll‐like receptor 2 and 3 agonists for safely enhancing antitumor immunity, Cancer Science, 106(12): 1659-1668. https://doi.org/10.1111/cas.12824 PMid:26395101 PMCid:PMC4714660 Stassijns J., Bollaerts K., Baay M., and Verstraeten T., 2016, A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children, Vaccine, 34(6): 714-722. https://doi.org/10.1016/j.vaccine.2015.12.024 PMid:26740250 Tan J., Ding B., Teng B., Ma P., and Lin J., 2022, Understanding structure-function relationships of nanoadjuvants for enhanced cancer vaccine efficacy, Advanced Functional Materials, 32(16): 2111670. https://doi.org/10.1002/adfm.202111670 Taylor D., Meyer C., Graves D., Sen R., Fu J., Tran E., Mirza B., Rodriguez G., Lang C., Feng H., Quaranta V., Wilson J., Kim Y., and Korrer M.J., 2022, MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses, Frontiers in Immunology, 13: 936129. https://doi.org/10.3389/fimmu.2022.936129 PMid:36059502 PMCid:PMC9437625 Thorne A., Malo K., Wong A., Nguyen T., Cooch N., Reed C., Yan J., Broderick K., Smith T., Masteller E., and Humeau L., 2020, Adjuvant screen identifies synthetic DNA-encoding Flt3L and CD80 immunotherapeutics as candidates for enhancing anti-tumor T cell responses, Frontiers in Immunology, 11: 327. https://doi.org/10.3389/fimmu.2020.00327 PMid:32161596 PMCid:PMC7052369 Wang T., 2024, The application prospects of immunomodulators in cancer treatment, Cancer Genetics and Epigenetics, 12(1): 1-7. https://doi.org/10.5376/cge.2024.12.0001 Wang W., 2024, Studying the dynamic changes of the immune system through single-cell omics, International Journal of Molecular Medical Science, 14(1): 29-41. https://doi.org/10.5376/ijmms.2024.14.0005 Yang J.X., Tseng J.C., Yu G.Y., Luo Y., Huang C.Y.F., Hong Y.R., and Chuang T.H., 2022, Recent advances in the development of toll-like receptor agonist-based vaccine adjuvants for infectious diseases, Pharmaceutics, 14(2): 423. https://doi.org/10.3390/pharmaceutics14020423 PMid:35214155 PMCid:PMC8878135
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==